Alendronate

Sharpe, Miriam; Noble, Stuart; Spencer, Caroline M.

doi:10.2165/00003495-200161070-00010

Cited by 61 publications

(15 citation statements)

References 146 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AL mainly acts on osteoclasts, while several studies have indicated its ability to enhance the differentiation of bone marrow cells, mesenchymal stem cells or adipose stem cells into osteoblasts (Duque and Rivas, 2007, Nishikawa et al, 1996, Wang et al, 2010, Wu et al, 2014). Based on these properties, AL may also be used in the treatment of periodontal defects, malignant hypercalcemia and orthopedic reconstruction (Samdancioglu et al, 2006, Sharpe et al, 2001). Novel studies, using Alendronate to prevent breast cancer bone metastasis, showed that it was an effective therapeutic drug and that it possesses antitumor and anti-angiogenic activities (Dong et al, 2018, Miller et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of Alendronate depot microspheres based on novel poly(-ε-caprolactone)/Vitamin E TPGS copolymers

Koulouktsi

Nanaki

Barmpalexis

et al. 2019

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Preparation and characterization of Alendronate depot microspheres based on novel poly(-ε-caprolactone)/Vitamin E TPGS copolymers

Koulouktsi

Nanaki

Barmpalexis

et al. 2019

International Journal of Pharmaceutics: X

View full text Add to dashboard Cite

show abstract

“…Alendronate, or alendronic acid, is a nitrogen-containing bisphosphonate that binds to bone surfaces and inhibits bone resorption by osteoclasts, possibly by inhibiting the mevalonate pathway. It has been shown to be effective in the treatment of women or men with corticosteroid-induced osteoporosis and in the prevention of osteoporosis in postmenopausal women [ 99 ]. Risedronate is a pyridinyl bisphosphonate capable of reducing the bone turnover process and decreasing bone resorption by interfering with the activity of osteoclasts and inhibiting their adhesion to the mineralized bone matrix without affecting its porosity [ 100 ].…”

Section: Treatment Of Osteoporosis and Novel Approachesmentioning

confidence: 99%

Current Status of the Diagnosis and Management of Osteoporosis

Aibar-Almazán

Voltes-Martínez

Castellote-Caballero

et al. 2022

IJMS

140

View full text Add to dashboard Cite

Osteoporosis has been defined as the silent disease of the 21st century, becoming a public health risk due to its severity, chronicity and progression and affecting mainly postmenopausal women and older adults. Osteoporosis is characterized by an imbalance between bone resorption and bone production. It is diagnosed through different methods such as bone densitometry and dual X-rays. The treatment of this pathology focuses on different aspects. On the one hand, pharmacological treatments are characterized by the use of anti-resorptive drugs, as well as emerging regenerative medicine treatments such as cell therapies and the use of bioactive hydrogels. On the other hand, non-pharmacological treatments are associated with lifestyle habits that should be incorporated, such as physical activity, diet and the cessation of harmful habits such as a high consumption of alcohol or smoking. This review seeks to provide an overview of the theoretical basis in relation to bone biology, the existing methods for diagnosis and the treatments of osteoporosis, including the development of new strategies.

show abstract

“…Alendronate belongs to the group of bisphosphonates and is already being applied in medical therapy and prophylactically for osteoporosis [9]. Bone structure is made denser by the consistent delivery of alendronate, making the bone less fracture prone [10,11]. These effects rely on inhibiting osteoclastic activity.…”

Section: Introductionmentioning

confidence: 99%

Alendronate Release from UHMWPE-Based Biomaterials in Relation to Particle Size of the GUR Powder for Manufacturing

et al. 2019

View full text Add to dashboard Cite

Ultra-high molecular weight polyethylene (UHMWPE) is widely used in endoprosthetics and has been the subject of countless studies. This project investigates the dependence of alendronate (AL) release on the molecular weight of the UHMWPE used (GUR1020 and GUR1050). A 0.5 wt% AL was added to the UHMWPE during the production of the moldings. In addition to the 14-day release tests, biocompatibility tests such as live dead assay, cell proliferation assay (WST) and Lactate dehydrogenase test (LDH) with MG-63 cells as well as a tensile test according to DIN EN ISO 527 were carried out. The released AL concentration was determined by HPLC. A continuous release of the AL was observed over the entire period of 2 weeks. In addition, a correlation between molar mass and AL release was demonstrated. The GUR1020 showed a release four times higher than the GUR1050. Both materials have no negative influence on the proliferation of MG-63 cells. This was also confirmed in the live/dead assay by the increase in cell count. No cytotoxicity was detected in the LDH test. The addition of 0.5 wt% AL increased the elongation at break for GUR1020 by 23% and for GUR1050 by 49%. It was demonstrated that the choice of UHMWPE has an influence on the release of AL. The particle size in particular has a strong influence on the release behavior.

show abstract

Alendronate

Cited by 61 publications

References 146 publications

Preparation and characterization of Alendronate depot microspheres based on novel poly(-ε-caprolactone)/Vitamin E TPGS copolymers

Preparation and characterization of Alendronate depot microspheres based on novel poly(-ε-caprolactone)/Vitamin E TPGS copolymers

Current Status of the Diagnosis and Management of Osteoporosis

Alendronate Release from UHMWPE-Based Biomaterials in Relation to Particle Size of the GUR Powder for Manufacturing

Contact Info

Product

Resources

About